We are committed to improving health and well-being around the world. From developing new therapies that treat and prevent disease to helping people in need, we are guided by a rich legacy and inspired by a shared vision.
Provides Guidance on First Quarter
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today re-confirmed its expectations for full-year 2012 non-GAAP EPS to be between $3.75 and $3.85, and the 2012 GAAP EPS range to be $2.04 to $2.30. The 2012 non-GAAP range excludes acquisition-related costs and costs related to restructuring programs.
As previously noted, Merck expects full-year 2012 revenues to be at or near 2011 levels on a constant currency basis. At current exchange rates, sales would be unfavorably affected by about 2 to 3 percent.
The company is providing guidance about its expectations for the first quarter of 2012 to help investors understand the impact of exchange in the quarter. With a first quarter Euro exchange rate of approximately $1.31/Euro, currency is expected to have approximately a 1 to 2 percent unfavorable impact on sales in the first quarter. Merck expects first-quarter non-GAAP EPS to be between $0.95 and $0.98, and the GAAP EPS range to be $0.52 to $0.60.
In addition, the company expects full-year 2012 non-GAAP R&D expense to be at approximately the same level as in 2011 and expects its full-year 2012 non-GAAP tax rate to be in the range of 23 to 25 percent.
A reconciliation of anticipated full-year and first-quarter 2012 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below.(1)
|$ in millions, except EPS amounts||Full Year 2012|
|GAAP EPS||$2.04 to $2.30|
|1.71 to 1.55|
|Non-GAAP EPS that excludes items listed below||$3.75 to $3.85|
|$5,200 to $4,900|
|Restructuring costs||1,100 to 800|
|Net decrease (increase) in income before taxes||6,300 to 5,700|
|Estimated income tax (benefit) expense||(1,110) to (985)|
|Decrease (increase) in net income||$5,190 to $4,715|
|$ in millions, except EPS amounts||First Quarter 2012|
|GAAP EPS||$0.52 to $0.60|
|Difference2||0.43 to 0.38|
|Non-GAAP EPS that excludes items listed below||$0.95 to $0.98|
|Acquisition-related costs3||$1,300 to $1,200|
|Restructuring costs||300 to 200|
|Net decrease (increase) in income before taxes||1,600 to 1,400|
|Estimated income tax (benefit) expense||(285) to (240)|
|Decrease (increase) in net income||$1,315 to $1,160|
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
(1) Both non-GAAP and GAAP EPS guidance for 2012 assume the potential exercise by AstraZeneca of its Shares Option in mid-2012 and include the estimated associated impact on revenue and equity income from affiliates. They do not reflect any gain on the potential transaction, which would be reflected only in the company's GAAP results.
(2) Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS which may be different than the amount calculated by dividing the impact of the excluded items by the weighted average shares.
(3) Includes expenses for the amortization of intangible assets and amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as intangible asset impairment charges. Also includes integration and other costs associated with mergers and acquisitions.
Ron Rogers, 908-423-6449
Alex Kelly, 908-423-5185